The office explained that the university's outpatient clinic began studying the relationship between cancer and obesity in 2021, focusing on the characteristics of obesity patterns and their impact on cancer development . Long-term follow-up results showed a strong correlation between obesity and several diseases , particularly metabolic syndrome and its various components.
Researchers have found that "female-type obesity" does not pose significant cardiovascular or metabolic risks, while abdominal obesity is associated with significant cardiovascular and metabolic risks, as well as an increased likelihood of developing tumors. Furthermore, some patients experience obesity with increased body fat and decreased muscle mass and strength, which increases the risks regardless of body mass index.
“Individuals with grade II and III obesity who successfully control their chronic diseases such as diabetes ,
hypertension and coronary heart disease, regulate key metabolic indicators such as glucose, cholesterol and uric acid, and regularly continue to take medications to lower blood pressure, lipids and blood sugar, show a significant reduction in the incidence of cancer,” said Inna Vasilieva, Associate Professor in the Department of Outpatient Therapy. “This means that successful treatment of chronic diseases may have a protective effect.”
Scientists have confirmed the essential role of abdominal obesity as a key component of metabolic syndrome in the development of cancer, noting that persistent abdominal obesity for more than 10 years with two or more components of metabolic syndrome significantly increases the risk of developing cancer.
Mikhail Osadchuk, head of the university's outpatient department, said:
"Based on the follow-up of 2,000 patients, we identified a group with the highest risk of developing cancer, which included patients with signs of abdominal obesity for more than 10 years, two or more components of metabolic syndrome, as well as a family history, lack of control over blood pressure, cholesterol and blood sugar, and not taking medications to treat other chronic diseases. These patients could be a target group for clinical examination and intensive follow-up ."
